Vialwirebiotech, curated
September 30, 2026, 4:47 PM
August 27, 2026
- 12:32 PM · BioPharma Dive12:32 PMMichael Polansky has a new, skin-focused biotech. Don’t call it a drug company. — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMFifth Circuit shuts down hope of circuit split on IRA challenges — BioWorld
- 9:40 AM · Pharmaceutical Technology9:40 AMSK inks $795m Biohaven epilepsy deal, entering potassium channel opener race — Pharmaceutical Technology
- 9:12 AM · Pharmaceutical Executive9:12 AM<![CDATA[Osivax And GC Biopharma Enter Collaboration to Develop Next Generation Influenza Vaccine ]]> — Pharmaceutical Executive
- 9:00 AM · BioWorld9:00 AMCEPI supports fifth Bundibugyo ebolavirus vaccine candidate — BioWorld
- 9:00 AM · BioWorld9:00 AMNoxopharm’s Sofra helps immune cells respond to dying cancer cells — BioWorld
- 6:36 AM · Pharmaceutical Technology6:36 AMFDA grants RPDD to ReviR’s RTX-117 for CMT — Pharmaceutical Technology
- 6:30 AM · STAT News
- 4:51 AM · Drug Discovery World4:51 AMKOALA trial launched to assess CAR-T for myeloma — Drug Discovery World
- 4:42 AM · Pharmaceutical Technology4:42 AMViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy — Pharmaceutical Technology
August 26, 2026
- 10:07 PM · SCMP — Tech10:07 PMChina’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial — SCMP — Tech
- 1:14 PM · Pharmaceutical Executive1:14 PM<![CDATA[FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer]]> — Pharmaceutical Executive
- 12:00 PM · BioWorld12:00 PMFresh evidence GSK’s shingles vaccine reduces cardiovascular risk — BioWorld
- 12:00 PM · BioWorld12:00 PMLicensing of pending patents can be an antitrust threat, FTC says — BioWorld
- 12:00 PM · BioWorld12:00 PMPolaryx raises $10M for phase II rare disease basket trial — BioWorld
- 12:00 PM · BioWorld12:00 PMDeals/M&As: Werewolf, Ambros combine in all-stock merger — BioWorld
- 11:23 AM · NYT — Health11:23 AMF.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer — NYT — Health
- 10:11 AM · BioPharma Dive10:11 AMZepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMRevier Therapeutics launches with cardiometabolic pipeline — BioWorld
- 6:52 AM · SCMP — Tech
- 6:40 AM · Pharmaceutical Technology6:40 AMMetsera backers establish new biotech armed with China-licensed immunology asset — Pharmaceutical Technology
- 6:08 AM · Pharmaceutical Technology6:08 AMJazz secures FDA approval for Ziihera in advanced HER2+ GEA — Pharmaceutical Technology
- 6:00 AM · Drug Discovery World6:00 AMJapanese regulator approves first functional cure for chronic hepatitis B — Drug Discovery World
- 4:46 AM · Pharmaceutical Technology4:46 AMMcKesson to acquire Precision Medicine Group for $2.25bn — Pharmaceutical Technology
- 4:00 AM · Drug Discovery World4:00 AMEC okays immunotherapy double regimen for multiple myeloma — Drug Discovery World
- 4:00 AM · Drug Discovery World4:00 AMWhen the world’s first solid-tumour CAR-T gets approved in China — Drug Discovery World
August 25, 2026
- 9:00 PM · SCMP — Tech9:00 PMChina rushes to develop Moderna-style cancer vaccines amid market frenzy — SCMP — Tech